electroCore, Inc.

NASDAQ:ECOR

Medical - Devices

Healthcare
$7.71 -5.70%

-$0.50 today

Market cap
$71.13M
Beta
0.87
P/E (TTM)
-4.8
EPS (TTM)
-$1.72
52W Low $4.16High $10.50

Volume 0.06M

Average 0.11M

ECOR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

electroCore, Inc.NASDAQ: ECOR

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.04M rose 91.9% year over year, ahead of the +26.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 120.4% from the prior quarter. Over 3 fiscal years it compounded at -10.4% a year.

Context

  • Stock-based compensation amounted to 6.0% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +91.9% holds above the trailing-twelve-month pace of +26.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.04M+120.4% QoQ
Last fiscal yearDec 2025
$1.93M+3.2% YoY
LTMMar 2026
$2.43M+26.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91.9%——
1 year+3.2%——
3-year CAGR-10.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
1.93M USD
Year-over-year change
+3.2%
4-year CAGR
-12.6%

Stock-Based Compensation vs competitors

How ECOR compares with its peers on the latest reported figures

  • ECOR's LTM Mar 2026 stock-based compensation of $2.43M is the 2nd largest of the 6 companies compared; the peer median is $2.14M.
  • Its year-over-year change of +26.0% is the 3rd highest of 5, against a peer median of +37.6%.
  • Stock-based compensation amounts to 7.0% of revenue for ECOR, versus a peer median of 87.0%.
ECOR Competitors Peer median
Stock-Based Compensation for ECOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$2.91M +50.5%+4.3%—
ECORelectroCore, Inc.LTM Mar 2026$2.43M +26.0%-10.4%7.0%
HYPDHyperion DeFi, Inc.LTM Jun 2026$2.22M -66.2%+19.2%158.7%
MYOMyomo, Inc.LTM Mar 2026$2.14M +95.6%+20.5%5.2%
RNXTRenovoRx, Inc.LTM Mar 2026$1.3M +24.7%+25.3%87.0%
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
Peer median (excluding ECOR) $2.14M+37.6%+19.8%87.0%

Competitors are the stored peer set for ECOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.22M)(22.16M)(18.83M)(11.89M)(13.97M)
Depreciation & Amortization382K548K1.03M1.26M1.68M
Deferred Income Tax00000
Stock-Based Compensation3.3M2.68M1.7M1.87M1.93M
Change in Working Capital1.63M2.04M815K1.76M1.33M
Accounts Receivables(217K)37K(262K)(710K)(142K)
Inventory371K296K96K713K16K
Accounts Payables464K1.19M35K1.05M2.45M
Other Working Capital1.01M519K946K708K(999K)
Other Non-Cash Items(1.72M)244K628K51K849K
Operating Cash Flow(13.63M)(16.65M)(14.67M)(6.95M)(8.19M)
Capital Expenditures00(206K)0(66K)
Acquisitions (Net)00000
Purchases of Investments(5.08M)00(8.52M)3.94M
Sales of Investments23.3M0000
Other Investing Activities00000
Investing Cash Flow18.22M0(206K)(8.52M)3.88M
Debt Repayment00007.41M
Common Stock Issued25.68M08.14M8.3M222K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(657K)139K0
Financing Cash Flow25.68M07.49M8.44M7.63M
Effect of Forex Changes175K(82K)6K147K18K
Net Change in Cash30.45M(16.73M)(7.38M)(6.88M)3.34M
Free Cash Flow(13.63M)(16.65M)(14.87M)(6.95M)(8.25M)

electroCore, Inc.

NASDAQ:ECOR

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.